About

Dr. Igor Kravets, MD, is a Clinical Professor of Medicine specializing in Endocrinology at Stony Brook University. He is based in Lake Grove, NY, and provides expert care in the field of endocrinology, diabetes, and metabolism. Dr. Kravets completed his fellowship at Stony Brook University Medical Center in 2007, following his residency in Internal Medicine at Jefferson Medical College of Thomas Jefferson University in 2004. He earned his medical degree from SUNY Syracuse Medical School in 2001. His professional expertise includes the diagnosis and treatment of hyperthyroidism, as evidenced by his publication on the topic in the American Family Physician journal in 2016. Dr. Kravets is board-certified in Endocrinology, Diabetes, and Metabolism by the American Board of Internal Medicine since 2007, and in Internal Medicine since 2005. He practices at Stony Brook Internists - Endocrinology, where he offers comprehensive endocrine care to his patients.

Research topics

• Medicine
• Internal medicine
• Emergency medicine
• Pathology
• Biology

Selected publications

• Bioethical Dignity as a Subject of International Biojurisprudence and Global Bioethics (Achievements, Prospects, Risks)

  STATE POWER AND LOCAL SELF-GOVERNMENT · 2025-11-13

  article1st authorCorresponding

  This article explores the concept, nature, and discursive scope of bioethical dignity as a metalegal and metaethical category in contemporary biojurisprudence. It demonstrates the relationship and interdependence of bioethical dignity and human rights in biomedicine, taking into account international debates and international and Russian biomedical law. International biojurisprudence seeks to link human dignity with human rights mechanisms in bioethics and biomedicine. The right to bioethical dignity extends to various living species, not just humans. In the 21st century, legal, ethical, and technological reasons have emerged to consider bioethical dignity in the context of the intergenerational relationship, the preservation of human nature, and ensuring humanitarian biosecurity against the risks posed by new technologies.

  PublisherDOI

• The Genetic Variations Affecting the Pathophysiology and Pharmacological Treatment of Type 2 Diabetes Mellitus

  Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · 2025-03-12

  articleOpen access1st authorCorresponding

  Type 2 diabetes mellitus is one of the leading causes of morbidity and mortality in the world. The two main components of the mechanism underlying T2DM are insulin resistance and impaired insulin secretion. The current algorithmic approach to the treatment of the disease does not take the individual genetic makeup of patients into consideration. However, multiple gene variants affect the efficacy and metabolism of antidiabetes medications. For example, MATE1 works in conjunction with OCT1 and OCT2 to regulate metformin elimination, the rs1801282 (Pro12Ala) single nucleotide polymorphism is associated with a better therapeutic response to pioglitazone across different populations, and the K allele of KCNJ11 rs5219 (E23K) polymorphism is associated with a greater HbA1c reduction in Caucasian and Chinese patients treated with gliclazide, a sulfonylurea. Modern genetic techniques have ushered in the era of pharmacogenomics and precision medicine, identifying genetic variations that can be translated into personalized treatment approaches, improved diabetes risk prediction, ethnic-specific insights, identification of new drug targets, and reduction of adverse drug reactions. Challenges in the implementation of pharmacogenomics in the treatment of Type 2 diabetes include modest effect sizes of many genetic variants, heterogeneity of the disease due to complex interactions between genetics, environment, and lifestyles, and the cost of genetic testing and analysis. This review summarizes the genetic variations affecting each major class of non-insulin anti-diabetes medications.

  PublisherDOI

• The Constitutional Court of the Russian Federation on the Protection and Defense of Human Dignity: The Problem of Legal Polymorphism and Legal Judicial Argumentation

  JURIST · 2025-04-24

  article1st authorCorresponding

  The article examines the current legal positions of the Constitutional Court of the Russian Federation on issues of protection and defense human dignity based on an interdisciplinary approach. It identifies the problems of legal interpretation of provisions on human dignity and the influence of constitutional justice on the assessment, application and development of sectoral legislation. Human dignity on the scales of constitutional justice is an anthropological, existential and legal category for assessing legal norms of various branches of Russian law.

  PublisherDOI

• Podocyte-specific KLF6 primes proximal tubule CaMK1D signaling to attenuate diabetic kidney disease

  Nature Communications · 2024-09-13 · 15 citations

  articleOpen access

  Diabetic kidney disease (DKD) is the main cause of chronic kidney disease worldwide. While injury to the podocytes, visceral epithelial cells that comprise the glomerular filtration barrier, drives albuminuria, proximal tubule (PT) dysfunction is the critical mediator of DKD progression. Here, we report that the podocyte-specific induction of human KLF6, a zinc-finger binding transcription factor, attenuates podocyte loss, PT dysfunction, and eventual interstitial fibrosis in a male murine model of DKD. Utilizing combination of snRNA-seq, snATAC-seq, and tandem mass spectrometry, we demonstrate that podocyte-specific KLF6 triggers the release of secretory ApoJ to activate calcium/calmodulin dependent protein kinase 1D (CaMK1D) signaling in neighboring PT cells. CaMK1D is enriched in the first segment of the PT, proximal to the podocytes, and is critical to attenuating mitochondrial fission and restoring mitochondrial function under diabetic conditions. Targeting podocyte-PT signaling by enhancing ApoJ-CaMK1D might be a key therapeutic strategy in attenuating the progression of DKD.

  PublisherOA PDFDOI

• 6566 Concurrent Papillary Craniopharyngioma and Growth Hormone-Secreting Pituitary Adenoma: A Rare Collision Tumor

  Journal of the Endocrine Society · 2024-10-01

  articleOpen accessSenior author

  Abstract Disclosure: A.J. Mancini: None. R. Mathew: None. J. Oentoro: None. A.M. Devine: None. C. Maxwell: None. I. Kravets: None. Introduction: Collision tumors, which consist of two or more histologically distinct tumors in the same anatomic location, are rare; when occurring in the sella, they more commonly consist of a pituitary adenoma and Rathke cleft cyst. Here, we present a case of a collision tumor consisting of a papillary craniopharyngioma and GH-secreting pituitary adenoma. Clinical Case: A 49-year-old man presented with two months of headaches and blurry vision. Physical exam showed frontal bossing, enlarged jaw and hands, and macroglossia. A visual field exam revealed bitemporal hemianopsia. Initial labs included PRL 105.2 ng/mL (4.0-15.2), TSH 0.399 uIU/mL (0.27-4.2), free T4 0.95 ng/dL (0.93-1.70), FSH 0.8 mIU/mL (1.5-12.4), LH 0.3 mIU/mL (1.7-8.6), total testosterone 10 ng/dL (300-890) drawn at 6:00 a.m., cortisol 8.5 ug/dL (6.0-18.4) and ACTH 32.1 pg/mL (7.2-63.3) drawn at 10:30 a.m.; an IGF-1 was not initially sent. Pituitary MRI showed a 4.1 cm mixed solid and cystic sellar/suprasellar mass with mass effect on the optic chiasm. The patient underwent a craniotomy with tumor resection on hospital day (HD) 5 with pathology showing a papillary craniopharyngioma. The next week, an elevated IGF-1 level of 517 ng/mL (68-225) prompted a GH suppression test. GH levels 1 and 2 hours after oral glucose load were 19.3 ng/mL (0.05-3.00) and 17.8 ng/mL respectively, confirming the diagnosis of acromegaly. On HD 20, repeat MRI showed an interval increase in the mass size with increased mass effect on the optic chiasm. A second craniotomy with an endoscopic resection of the mass was performed, with pathology again showing a papillary craniopharyngioma. Post-operative MRI showed a residual mass with mild mass effect on the optic chiasm for which the patient began radiation therapy. Interval MRI demonstrating a further increase in the tumor size plus a rising IGF-1 level of 700 ng/mL and ongoing lack of GH suppression with an oral glucose load prompted a transsphenoidal resection of the tumor on HD 54. The pathology showed a growing residual papillary craniopharyngioma and a component of a PIT1 lineage adenoma, the majority of which expressed GH. The patient developed numerous complications during his hospitalization and ultimately passed away on HD 64. Conclusion: There are 22 reported cases of collision tumors of pituitary adenomas and craniopharyngiomas, and only five secreted GH. Moreover, four of the five cases described collision tumors with an adamantinomatous craniopharyngioma; the fifth case did not include data on the type of craniopharyngioma (1). Therefore, to the best of our knowledge, our case represents the first collision tumor of a GH-secreting pituitary adenoma and papillary craniopharyngioma. Reference: (1) Hasegawa H, Jentoft ME, Young WF, et al. Collision of Craniopharyngioma and Pituitary Adenoma: Comprehensive Review of an Extremely Rare Sellar Condition. World Neurosurg. 2021;149:e51-e62. Presentation: 6/3/2024

  PublisherDOI

• Concurrent Papillary Craniopharyngioma and Growth Hormone-Secreting Pituitary Adenoma: A Rare and Aggressive Collision Tumor

  AACE Clinical Case Reports · 2024-04-16 · 4 citations

  articleOpen accessSenior authorCorresponding

  Background/Objective: Collision tumors composed of craniopharyngiomas and pituitary adenomas are extremely rare. We report a collision tumor formed by a papillary craniopharyngioma and a growth hormone-secreting pituitary adenoma, which is the first report of such a tumor, to the best of our knowledge. Case Report: A 49-year-old man presented with 2 months of headaches and blurry vision. An exam demonstrated frontal bossing, enlarged jaw and hands, macroglossia, and bitemporal hemianopsia, and magnetic resonance imaging (MRI) showed a 4.1 cm sellar/suprasellar mass with mass effect on the optic chiasm. The tumor was resected twice via a craniotomy, the second time due to interval growth, with the pathology after both surgeries showing a papillary craniopharyngioma. IGF-1 was 517 ng/mL (68-225) and growth hormone suppression test was positive. Repeat MRI showed residual tumor with ongoing mass effect on the optic chiasm and radiation therapy was initiated. MRI showed interval growth of the mass and IGF-1 rose to 700 ng/mL after which the patient underwent a transsphenoidal resection of the tumor; the pathology showed a residual papillary craniopharyngioma and a PIT1 lineage adenoma with most cells expressing growth hormone. After developing numerous complications, the patient passed away. Discussion: Collision tumors of the sella are often associated with an aggressive clinical course, as they often go undiagnosed preoperatively, thus reducing the likelihood of total resection and leading to higher rates of craniopharyngioma recurrence. Conclusion: A pituitary mass with an aggressive clinical course should prompt a high index of suspicion for a sellar collision tumor, though prognosis remains poor.

  PublisherOA PDFDOI

• ГРУПИ КРОВІ АВO ТА РЕЗИСТЕНТНІСТЬ ДО COVID-19

  Інфекційні хвороби · 2023-05-30

  articleOpen accessSenior author

  Узагальнено та систематизовано дані наукової літератури про роль груп крові за системою АВО у сприйнятливості до інфікування SARS-CoV-2. Група крові II (А) пов’язана з більшою чутливістю до COVID-19, тоді як група I (О) демонструє підвищену резистентність до коронавірусної інфекції. Наявність анти-ОА антитіл знижує сприйнятливість осіб з I (О) групою крові до COVID-19. Підвищення активності АПФ-2 у людей з II (А) групою крові та надмірне утворення плазмових факторів коагуляції фон Віллебранда та VIII можуть сприяти розвитку ускладнень при COVID-19.

  PublisherOA PDFDOI

• Outcomes and Healthcare Provider Perceptions of Real-Time Continuous Glucose Monitoring (rtCGM) in Patients With Diabetes and COVID-19 Admitted to the ICU

  Journal of Diabetes Science and Technology · 2021-01-12 · 39 citations

  articleOpen access

  Objective: We assessed the clinical utility and accuracy of real-time continuous glucose monitoring (rtCGM) (Dexcom G6) in managing diabetes patients with severe COVID-19 infection following admission to the intensive care unit (ICU). Methods: We present retrospective analysis of masked rtCGM in 30 patients with severe COVID-19. rtCGM was used during the first 24 hours for comparison with arterial-line point of care (POC) values, where clinicians utilized rtCGM data to adjust insulin therapy in patients if rtCGM values were within 20% of point-of-care (POC) values during the masked period. An investigator-developed survey was administered to assess nursing staff ( n = 66) perceptions regarding the use of rtCGM in the ICU. Results: rtCGM data were used to adjust insulin therapy in 30 patients. Discordance between rtCGM and POC glucose values were observed in 11 patients but the differences were not considered clinically significant. Mean sensor glucose decreased from 235.7 ± 42.1 mg/dL (13.1 ± 2.1 mmol/L) to 202.7 ± 37.6 mg/dL (11.1 ± 2.1 mmol/L) with rtCGM management. Improvements in mean sensor glucose were observed in 77% of patients ( n = 23) with concomitant reductions in daily POC measurements in 50% of patients ( n = 15) with rtCGM management. The majority (63%) of nurses reported that rtCGM was helpful for improving care for patients with diabetes patients during the COVID-19 pandemic, and 49% indicated that rtCGM reduced their use of personal protective equipment (PPE). Conclusions: Our findings provide a strong rationale to increase clinician awareness for the adoption and implementation of rtCGM systems in the ICU. Additional studies are needed to further understand the utility of rtCGM in critically ill patients and other clinical care settings.

  PublisherOA PDFDOI

• Impact of preoperative antibiotics and other variables on integrated microbiome-host transcriptomic data generated from colorectal cancer resections

  World Journal of Gastroenterology · 2021-04-09 · 8 citations

  articleOpen access

  BACKGROUND: Integrative multi-omic approaches have been increasingly applied to discovery and functional studies of complex human diseases. Short-term preoperative antibiotics have been adopted to reduce site infections in colorectal cancer (CRC) resections. We hypothesize that the antibiotics will impact analysis of multi-omic datasets generated from resection samples to investigate biological CRC risk factors. AIM: To assess the impact of preoperative antibiotics and other variables on integrated microbiome and human transcriptomic data generated from archived CRC resection samples. METHODS: Genomic DNA (gDNA) and RNA were extracted from prospectively collected 51 pairs of frozen sporadic CRC tumor and adjacent non-tumor mucosal samples from 50 CRC patients archived at a single medical center from 2010-2020. The 16S rRNA gene sequencing (V3V4 region, paired end, 300 bp) and confirmatory quantitative polymerase chain reaction (qPCR) assays were conducted on gDNA. RNA sequencing (IPE, 125 bp) was performed on parallel tumor and non-tumor RNA samples with RNA Integrity Numbers scores ≥ 6. RESULTS: nontumor groups, and detected significantly reduced bacterial load in the (+)antibiotics group. Principal coordinate analysis of the transcriptomic data showed a clear separation between tumor and nontumor samples. Differentially expressed genes obtained from separate analyses of tumor and nontumor samples, are presented for the antibiotics, CRC location, diabetes and Black/AA race groups. CONCLUSION: in tumor.

  PublisherOA PDFDOI

• The Role of Podocytes and Podocyte-Associated Biomarkers in Diagnosis and Treatment of Diabetic Kidney Disease

  Journal of the Endocrine Society · 2020-03-05 · 76 citations

  reviewOpen access1st authorCorresponding

  Diabetic kidney disease (DKD) is an important public health problem. Podocyte injury is a central event in the mechanism of DKD development. Podocytes are terminally differentiated, highly specialized glomerular visceral epithelial cells critical for the maintenance of the glomerular filtration barrier. Although potential mechanisms by which diabetic milieu contributes to irreversible loss of podocytes have been described, identification of markers that prognosticate either the development of DKD or the progression to end-stage kidney disease (ESKD) have only recently made it to the forefront. Currently, the most common marker of early DKD is microalbuminuria; however, this marker has significant limitations: not all diabetic patients with microalbuminuria will progress to ESKD and as many as 30% of patients with DKD have normal urine albumin levels. Several novel biomarkers indicating glomerular or tubular damage precede microalbuminuria, suggesting that the latter develops when significant kidney injury has already occurred. Because podocyte injury plays a key role in DKD pathogenesis, identification of markers of early podocyte injury or loss may play an important role in the early diagnosis of DKD. Such biomarkers in the urine include podocyte-released microparticles as well as expression of podocyte-specific markers. Here, we review the mechanisms by which podocyte injury contributes to DKD as well as key markers that have been recently implicated in the development and/or progression of DKD and might serve to identify individuals that require earlier preventative care and treatment in order to slow the progression to ESKD.

  PublisherOA PDFDOI

Frequent coauthors

• Joshua D. Miller

  Stony Brook University

  13 shared

• Mary C. Rieff

  Stony Brook Medicine

  9 shared

• Eric J. Morley

  Stony Brook Medicine

  9 shared

• Marina Charitou

  Stony Brook Medicine

  9 shared

• Rajarsi Gupta

  9 shared

• Danielle J. Kelly

  Stony Brook University

  9 shared

• Patricia A. Skala

  Stony Brook School

  9 shared

• Kenneth W. Chow

  UCLA Medical Center

  9 shared